LOAMU
SRPT icon

Lombard Odier Asset Management (USA)’s Sarepta Therapeutics SRPT Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-30,000
Closed -$1.01M – 251
2017
Q2 		$1.01M Hold
30,000
– – 0.08% 187
2017
Q1 		$888K Buy
+30,000
New +$928K 0.08% 174

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TCP
Tourbillon Capital Partners New York $6.26M AUM 42.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s SRPT Position: Q3 2017 in Review

Lombard Odier Asset Management (USA) sold out of Sarepta Therapeutics (SRPT) in Q3 2017, closing a stake of 30,000 shares — an estimated $1.01M sold.

Lombard Odier Asset Management (USA) first reported a position in SRPT in Q1 2017 and held it in 2 quarters. The position peaked at $1.01M in Q2 2017. 233 funds tracked by Wall St. Rank hold SRPT as of Q3 2017.

  • Lombard Odier Asset Management (USA) reported no remaining Sarepta Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 30,000 Sarepta Therapeutics shares in Q3 2017, an estimated $1.01M.
  • Lombard Odier Asset Management (USA) first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 2 quarters.
  • Lombard Odier Asset Management (USA)'s Sarepta Therapeutics position peaked at $1.01M in Q2 2017.
  • 233 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2017.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q3 2017, filed 14 Nov 2017.